Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 09:30AM ET
10.49
Dollar change
-0.38
Percentage change
-3.50
%
Index- P/E- EPS (ttm)-9.03 Insider Own0.25% Shs Outstand5.89M Perf Week-3.14%
Market Cap61.79M Forward P/E- EPS next Y-4.95 Insider Trans0.00% Shs Float5.88M Perf Month7.37%
Income-47.41M PEG- EPS next Q-2.04 Inst Own34.81% Short Float0.81% Perf Quarter-25.60%
Sales10.02M P/S6.17 EPS this Y30.82% Inst Trans-73.54% Short Ratio1.40 Perf Half Y21.84%
Book/sh3.34 P/B3.14 EPS next Y20.09% ROA-50.40% Short Interest0.05M Perf Year-6.36%
Cash/sh9.56 P/C1.10 EPS next 5Y- ROE-143.19% 52W Range3.80 - 20.00 Perf YTD-17.73%
Dividend Est.- P/FCF- EPS past 5Y14.56% ROI-74.36% 52W High-47.55% Beta3.72
Dividend TTM- Quick Ratio4.51 Sales past 5Y-0.68% Gross Margin88.74% 52W Low176.05% ATR (14)0.60
Dividend Ex-Date- Current Ratio4.51 EPS Y/Y TTM25.89% Oper. Margin-482.21% RSI (14)51.32 Volatility6.44% 5.74%
Employees49 Debt/Eq2.31 Sales Y/Y TTM-1.37% Profit Margin-473.04% Recom1.33 Target Price21.75
Option/ShortNo / Yes LT Debt/Eq2.24 EPS Q/Q13.65% Payout- Rel Volume1.80 Prev Close10.87
Sales Surprise-10.81% EPS Surprise4.10% Sales Q/Q-6.62% EarningsFeb 08 BMO Avg Volume34.22K Price10.49
SMA201.98% SMA502.15% SMA200-3.70% Trades Volume3,082 Change-3.50%
Date Action Analyst Rating Change Price Target Change
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
08:00AM Loading…
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
08:56AM Loading…
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
08:00AM
Jun-30-23 06:50AM
Jun-06-23 06:54AM
May-15-23 11:33AM
May-05-23 07:30AM
05:45PM Loading…
May-04-23 05:45PM
04:26PM
04:01PM
Apr-27-23 04:01PM
Apr-17-23 08:12AM
Apr-05-23 08:13PM
Apr-03-23 08:00AM
Mar-14-23 11:02AM
Mar-13-23 10:21PM
09:15AM
08:00AM
Mar-08-23 07:09PM
Mar-02-23 04:01PM
Jan-20-23 10:09AM
Dec-12-22 10:00AM
Dec-05-22 11:08PM
Nov-12-22 07:43AM
Nov-10-22 02:30PM
Nov-09-22 05:45PM
04:01PM
08:27AM
Nov-07-22 04:01PM
Nov-02-22 04:00PM
Oct-07-22 04:01PM
Oct-03-22 04:01PM
Sep-19-22 09:16PM
Sep-07-22 08:00AM
Aug-31-22 12:53PM
Aug-30-22 08:52AM
08:00AM
Aug-19-22 12:25PM
Aug-18-22 08:49AM
08:00AM
Aug-13-22 10:05AM
Aug-05-22 03:30AM
Aug-04-22 06:25PM
04:01PM
Jul-29-22 04:00PM
Jul-28-22 04:00PM
Jul-08-22 07:56AM
Jul-07-22 04:01PM
Jun-10-22 07:00AM
Jun-06-22 07:48AM
Jun-04-22 09:00AM
Jun-02-22 08:00AM
06:46AM
May-12-22 10:26AM
May-11-22 08:59AM
May-06-22 01:01AM
May-05-22 06:05PM
04:01PM
May-04-22 09:35AM
Apr-28-22 04:00PM
Apr-21-22 07:28AM
Apr-12-22 11:57AM
Apr-11-22 08:00AM
Apr-07-22 04:01PM
Apr-05-22 08:00AM
Apr-04-22 08:53AM
07:50AM
07:00AM
Mar-07-22 11:03AM
Mar-04-22 04:40AM
Feb-25-22 07:30AM
Feb-24-22 05:40PM
04:01PM
Feb-17-22 04:00PM
Jan-31-22 05:38PM
Jan-20-22 08:00AM
Jan-14-22 11:33AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.